Chongyao Holdings Progress in Share Repurchase: Spent 80.9988 million yuan, totaling 15.4066 million shares repurchased

Log in to the Sina Finance app and search for 【Information Disclosure】 to view more evaluation grades

Chongqing Pharmaceutical Holding Co., Ltd. (hereinafter referred to as “Chongqing Pharmaceutical Holding”) issued an announcement on April 2 on the progress of its share repurchase, disclosing the implementation status of the share repurchase as of March 31, 2026. The announcement shows that the company has cumulatively repurchased 15.4066 million shares, accounting for 0.8915% of the total share capital, and has paid a total amount of approximately RMB 80.99 million (RMB 80,998.76598), which is close to the repurchase funding lower limit set earlier.

Repurchase progress: spent more than RMB 80 million, close to the lower limit

According to the announcement, as of March 31, 2026, Chongqing Pharmaceutical Holding, through a dedicated securities account for share repurchases and by using centralized bidding transactions, has cumulatively repurchased 15.41M shares (i.e., 15.4066 million shares), representing approximately 0.8915% of the company’s total share capital. During the repurchase period, the highest transaction price was RMB 5.48 per share and the lowest transaction price was RMB 5.01 per share. The total amount paid was RMB 80,998,765.98 (excluding transaction fees), which is equivalent to approximately RMB 80.99 million.

Under the previous plan, the total repurchase funding for this round by Chongqing Pharmaceutical Holding is in the range of no less than RMB 80 million (including this figure) and no more than RMB 100 million (including this figure). The repurchase price shall not exceed RMB 6.6 per share. The repurchase period is within 12 months from the date the shareholders’ meeting approves the matter (i.e., July 28, 2025 to July 27, 2026). Based on the current progress, the company has already used RMB 80.99 million, which exceeds the lower limit of RMB 80 million and represents 80.99% of the maximum repurchase amount.

Repurchase background: sources of funds and purposes are clear

Looking back at the announcement, on July 10, 2025, Chongqing Pharmaceutical Holding held its 15th meeting of the ninth session of the board of directors, and on July 28, 2025, it held the 2025 third extraordinary general meeting of shareholders, approving the “Proposal on Repurchasing the Company’s Shares.” Under the plan, the company intends to use its own funds and a special loan for share repurchase. It will repurchase A-share shares through the centralized bidding transaction method on the SZSE. The purpose of the repurchase is “to reduce the company’s registered capital.”

Compliance note: strictly following trading rules

The announcement also emphasizes that during the repurchase period, the company strictly complied with relevant regulations and did not carry out repurchases during periods such as “the occurrence or decision-making process of major matters that may have a significant impact on the trading price of securities, up to the date of disclosure.” In addition, the entrusted prices and trading time slots for the centralized bidding transactions met regulatory requirements, and no violations such as “entrusted prices being at the daily price increase limit” or “entrustments made during the opening/closing call auction time slots” occurred.

Next steps: will continue to implement the repurchase based on market conditions

Chongqing Pharmaceutical Holding states that going forward, it will continue to implement this repurchase plan within the repurchase period according to market conditions, and will fulfill its information disclosure obligations in a timely manner in accordance with relevant regulations. Investors may pay attention to the company’s subsequent announcements and note investment risks.

This repurchase is an important measure by Chongqing Pharmaceutical Holding based on its confidence in the company’s future development, optimizing its capital structure by reducing registered capital. Up to now, the repurchase implementation progress meets the expectations of the plan. The subsequent use of funds and repurchase of shares still need to be continuously monitored.

Statement: There are risks in the market; invest with caution. This article is automatically published by an AI large model based on third-party databases and does not represent views of Sina Finance. Any information appearing in this article is for reference only and does not constitute personal investment advice. If there are discrepancies, please refer to the actual announcement. If you have any questions, please contact biz@staff.sina.com.cn.

Click to view the full text of the original announcement>>

Endless information and precise analysis are available on the Sina Finance app

Responsible editor: Xiao Lang Express News